Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Pilot Randomized Controlled Study of Combinatorial Gerotherapeutics for Healthspan Improvement

Authors not listed

AgelessRx · 2025

Deregulated nutrient-sensing Rapamycin / mTOR inhibition Metformin Human Randomized controlled trial

Abstract

This study is a 90-day interventional, randomized, controlled pilot trial exploring multi-modal gerotherapies and their impact on longevity-related outcomes. In this proof-of-concept phase, a small sample size of up to 30 subjects (10 subjects in each arm) will be randomized into one of the three arms: 1) Control, 2) Multi-therapy (B12, Naltrexone, Metformin, and NAD+), or 4) Comprehensive Therapy (mTOR-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">Rapamycin, Naltrexone, Metformin, B12, NAD+, GSH, and Infinite Supplement).

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-10-13 MST

Cite this

APA

Anonymous. (2025). A Pilot Randomized Controlled Study of Combinatorial Gerotherapeutics for Healthspan Improvement. <em>AgelessRx</em>. https://clinicaltrials.gov/study/NCT07475546

Vancouver

Anonymous. A Pilot Randomized Controlled Study of Combinatorial Gerotherapeutics for Healthspan Improvement. AgelessRx. 2025.

BibTeX

@misc{anon2025APilot, title = {A Pilot Randomized Controlled Study of Combinatorial Gerotherapeutics for Healthspan Improvement}, author = {Anonymous}, journal = {AgelessRx}, year = {2025}, }